NCT02340078已完成不适用
A Randomized, Multi Center, Double-blind, Active-controlled, Matched Pairs Design Clinical Study to Evaluate the Efficacy and Safety of HA IDF II Plus Versus HA IDF II in Nasolabial Fold Injection
LG Life Sciences0 个研究点目标入组 62 人开始时间: 2013年11月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 62
- 主要终点
- Proportion of the Subjects With at Least 10mm Difference in VAS Pain Scale Scores Within the Subject (VAS of the Control Device - VAS of the Test Device) Immediately After Treatment With the Investigational Devices
研究概览
简要总结
The objective of this study was to evaluate the efficacy and safety of HA IDF II plus (with lidocaine) injected in the nasolabial fold compared to HA IDF II (without lidocaine).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women aged between 30 and 60
- •Those whose wrinkles in the treatment area (nasolabial fold) correspond to Stage 3 or 4 in the 5-stage Wrinkle Severity Rating Scale (WSRS) symmetrically
- •Those who were informed on the purpose, method, and effect etc. of this study and signed the informed consent form
- •Those who fell under any of the following 3 cases:
- •Surgically sterile women
- •Women in menopause over 2 years from the last menstruation, aged at least 45
- •Among the women meeting neither of a nor b, those who agreed to use at least 2 contraception methods specified below (one of the barrier methods must be included) until 14 days after the last treatment with the investigational device
- •Barrier methods: Condom, diaphragm, cervical cap (pessary), spermicide
- •Hormonal methods: Pills, injection (depot), skin patch, hormonal implant (Implanon), vaginal ring
- •Intrauterine devices (IUDs): Cooper IUD (Loop), hormonal IUD (Mirena)
- •Natural methods: Basic body temperature, ovulation period, coitus interruptus, abstinent
排除标准
- •Those with a skin disease (skin infection, eczema, psoriasis, rosacea, herpes etc.) in the lower 2/3 part of the face in which the wrinkle evaluation may be affected
- •Patients with a malignant tumor recognized medically important and considered as potentially affecting the clinical study
- •Women in pregnancy or lactation
- •Those with the bilirubin level exceeding 1.5 times of the upper limit of normal or the ALT/AST level exceeding 2.5 times of the upper limit of normal
- •Those with the confirmed infection of syphilis or HIV
- •Those who had an anticoagulant therapy or antiplatelet therapy within 2 weeks prior to Visit 1 (screening)
- •Those who used a topical preparation (steroid, retinoid) in the facial area within 4 weeks prior to Visit 2 (randomization )
- •Those who experienced a deep chemical peeling or a procedure judged as potentially affecting the clinical study within 3 months prior to Visit 2 (randomization)
- •Those who experienced a non-permanent filler procedure or a cosmetic surgery in the face within 9 months prior to Visit 2 (randomization)
- •Those who had an implantation procedure with a permanent substance (silicone, PAAG, PMMA, CaHA etc.) in the treatment area (nasolabial fold )
- •Those currently with a streptococcal disease
- •Those with a history of severe allergy or hypersensitivity (anaphylaxis) judged as potentially affecting the clinical study
- •Those with a history of hypertrophic scar or keloid
- •Those with a history of bleeding disorder
- •Those with a hypersensitivity to the investigational device of this clinical study or lidocaine
- •Those who refused to agree not to use a local or systemic pain-relieving agent or other pain-relieving method (e.g.: ice pack) from the midnight of the treatment day with the investigational device through the post-measurement of the last VAS pain scale
- •Those who had participated in another clinical study within 1 month prior to Visit 1 (screening)
- •Those judged by the investigator as ineligible for this clinical study
结局指标
主要结局
Proportion of the Subjects With at Least 10mm Difference in VAS Pain Scale Scores Within the Subject (VAS of the Control Device - VAS of the Test Device) Immediately After Treatment With the Investigational Devices
时间窗: Visit 2 (week 0, immediately after treatment)
The degree of pain was evaluated by VAS (Visual Analog Scale), measuring the length from the left and to the mark by the subject in millimeter (mm) unit.
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Classic Plus Versus YVOIRE Classic in Nasolabial Fold InjectionWrinklesNCT02340091LG Life Sciences62
已完成
不适用
Clinical Study to Evaluate the Correction of Wrinkles and Folds and Safety of YVOIRE Classic Versus Restylane in Nasolabial Fold Intradermal InjectionTemporary Correction of WrinklesNCT03738020LG Life Sciences58
撤回
2 期
Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in ChildrenPainNCT02542098Purdue Pharma LP
尚未招募
4 期
Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis PatientsAnemia in Incident Dialysis PatientsNCT04134026Second Xiangya Hospital of Central South University400
招募中
1 期
A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS PatientsAmyotrophic Lateral SclerosisALSNCT06513546PLL TX AUSTRALIA PTY LTD153